Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

PRAGMA

Drug and asset intelligence for PRAGMA with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Stage
Development stage unavailable

Recent signals(2)

RegulatoryAugust 8, 2026

FDA Accepts Supplement for KEFLEX (Cephalexin) by PRAGMA

The FDA has accepted a supplemental application for KEFLEX (Cephalexin) from PRAGMA.

RegulatoryAugust 6, 2026

FDA Approves Supplemental Application for KEFLEX (Cephalexin)

The FDA has approved a supplemental application for KEFLEX, an antibiotic with cephalexin as its active ingredient.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Therapeutic areas

Antibiotic →
Infectious Disease →
Infectious Disease · Antibiotic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.